All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2017-12-05T10:00:01.000Z

Otlertuzumab to be evaluated for PTCL in phase II trials

By Sara Valente
Dec 5, 2017
Share:

Bookmark this article

On 28th November 2017, Aptevo Therapeutics announced in a press release their decision to investigate the use of otlertuzumab in peripheral T-cell lymphoma (PTCL). Scott Stromatt, Chief Medical Officer, commented that “intriguing evidence has been reported on the overexpression of CD37 on T-cell malignancies, suggesting a potential role for otlertuzumab in an attractive, orphan drug-eligible indication with high unmet medical need”. This evidence is promising as there are limited options for patients with this type of rare and aggressive non-Hodgkin lymphoma.

Otlertuzumab is a humanized monospecific antibody that targets CD37 that is currently being evaluated in the use of chronic lymphocytic leukemia (CLL) in combination with other drugs. Aptevo Therapeutics plans to assess the safety and efficacy of otlertuzumab in combination with bendamustine in patients who have relapsed or refractory PTCL.

More about...
Mature T and NK cell neoplasmsPeripheral T-cell lymphoma

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Epigenetics in peripheral T-cell lymphoma (PTCL)

Epigenetic dysregulation is found in many malignancies and has been the subject of targeted drug development studies.

Jul 9, 2019
Add bookmark

Epigenetics in peripheral T-cell lymphoma (PTCL)

Epigenetic dysregulation is found in many malignancies and has been the subject of targeted drug development studies.

Jul 9, 2019
Add bookmark

Alemtuzumab and CHOP for aggressive T-cell lymphoma

In this phase I, dose escalation trial, the authors investigated the possibility of combining CHOP chemotherapy with alemtuzumab, as a potential regimen against aggressive T-cell lymphoma.

Feb 25, 2019
Add bookmark

Alemtuzumab and CHOP for aggressive T-cell lymphoma

In this phase I, dose escalation trial, the authors investigated the possibility of combining CHOP chemotherapy with alemtuzumab, as a potential...

Feb 25, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox